Hyundai Bio Submits Clinical Phase 2 Trial Plan Application for COVID-19 Treatment

[Asia Economy Reporter Minji Lee] Hyundai Bio announced on the 21st that it has submitted the phase 2 clinical trial application for the COVID-19 treatment CP-COV03 to the Ministry of Food and Drug Safety.

The company stated, "Niclosamide is expected to have high antiviral efficacy against coronaviruses, but it has low bioavailability," and added, "CP-COV03 improves the bioavailability of niclosamide, raising expectations for its potential as a COVID-19 treatment."